Live
- Ola lists new prices on S1 X range
- Vivo unveils T3x 5G
- India’s dependency on crude imports at new high
- S.Korean Health Minister renews commitment to accomplish medical reform
- Vemireddy Prashanthi Reddy Files Nomination as Kovuru Assembly Candidate with Strong Support from Alliance Leaders
- UNCTAD pegs GDP growth forecast at 6.5% this year
- Thousands flock to support Alla Nani in Eluru as he files nomination for 7th time
- Multiple Candidates File Nomination Papers for Ongole Lok Sabha Constituency
- Massive Support for Narayana in Nellore City Constituency
- Twitch Introduces TikTok-Inspired Discovery Feed for Users
GSK, Pfizer get nod for consumer healthcare JV
The Competition Commission on Friday said it has approved the formation of a joint venture for consumer healthcare products by pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer.
New Delhi: The Competition Commission on Friday said it has approved the formation of a joint venture for consumer healthcare products by pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer.
GSK, in December 2018, had said it has reached an agreement with Pfizer to combine their consumer health businesses into a new joint venture (JV) with combined sales of around $12.7 billion (around
Rs 88,900 crore).
In a tweet, the Competition Commission of India (CCI) said it "approves formation of a JV for consumer healthcare products by GSK and Pfizer."
The proposed combination involves acquisition of Pfizer's consumer healthcare business by GSK, and the combination of GSK and Pfizer consumer healthcare business into a global consumer healthcare joint venture under the sole control of GSK, as per a notice submitted to CCI.
